Under-fire drug giant Valeant Pharmaceuticals International won't put Bausch & Lomb on the block, investor Bill Ackman told CNBC.
"It's a core asset," Ackman said. "We're only considering selling non-core assets."
On Wednesday, the activist investor and long-time Valeant stakeholder told an investor call that he expected to make back his losses on the drug company, which has had a disastrous six months, including accounting misstatements and concerns over its ties to specialty pharmacy Philidor.
Ackman's fund, Pershing Square, has lost about $1 billion on Valeant since taking a stake in March 2015. The stock closed up 3.9 percent at $35.51 on Thursday ET but is currently down more than 86 percent from an August 2015 high of $262.52 and fell as low as $26.11 last week.